Back

prof. dr. H.M. (Helena) Verkooijen

Full Professor

  • Clinical Trial Office
  • Julius Center Research Program Cancer

prof. dr. H.M. (Helena) Verkooijen

Research Programs

Biography

Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Leader (PI) of several international (H2020) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member.

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).

I lead two international consortia (one H2020 European, one transatlantic) and collaborate closely with (international) academic and industry partners. I am regularly invited as speaker at international conferences, educational sessions and consortium meetings, and as panelist at meetings/debates of professional organizations. I serve as a member in several scientific advisory boards and expert committees.

I am Strategic Advisor for 'NTvG Gezonde Zorg', a campaign of the Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde). This campaign contributes to ensuring sustainability and affordability of health care in the Netherlands by exposing the harms of medicalisation (overdiagnosis and overtreatment) and explicitly demonstrating the power of (primary) prevention. 

Side Activities

    • Strategic Advisor 'NTvG Gezonde Zorg'
    • Board Member Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep, BOOG)
    • Member Scientific Advisory Board Dutch Expert Centre for Screening
    • Board Member J.M. Fentener van Vlissingen Fonds
    • Member Scientific Advisory Board Dutch Prospective Colorectal Cancer Cohort (PLCRC)
    • Member Expert Committee Value-Based Health Care Breast Cancer (NFU)

Research Output (289)

Pre-treatment expectations of patients with spinal metastases:what do we know and what can we learn from other disciplines? A systematic review of qualitative studies

Gal R, Oostinga D, Wessels H, Verlaan J J, Charest-Morin R, Fisher C G, Verkooijen H M, Versteeg A L 9 dec 2020, In: BMC Cancer. 20 , p. 1212

Assessing the effect of hyperbaric oxygen therapy in breast cancer patients with late radiation toxicity (HONEY trial):a trial protocol using a trial within a cohort design

Batenburg M C T, van den Bongard H J G D, Kleynen C E, Maarse W, Witkamp A, Ernst M, Doeksen A, van Dalen T, Sier M, Schoenmaeckers E J P, Baas I O, Verkooijen H M 27 nov 2020, In: Trials. 21 , p. 980

Patient Reported Outcomes of Early-Stage Breast Cancer Patients after Different Radiotherapy Regimes

Jacobs D., Charaghvandi R. K., Horeweg N., Maduro J. H., II, Speijer G., Roeloffzen E. M. A., Fisscher U., Mast M., Bantema-Joppe E. J., Petoukhova A., van den Bongard H. J. G. D., Koper P., Crijns A. P. G., Marijnen C., Verkooijen H. 1 nov 2020, In: International Journal of Radiation Oncology Biology Physics. 108 , p. E25-E26

Oncology patients were found to understand and accept the Trials within Cohorts design

Young-Afat Danny A., Gal Roxanne, Gerlich Sophie, Burbach Johannes P.M., van der Velden Joanne M., van den Bongard Desireé H.J.G., Intven Martijn P.W., Kasperts Nicolien, May Anne M., van der Graaf Rieke, van Gils Carla H., Verkooijen Helena M. 31 okt 2020, In: Journal of Clinical Epidemiology. 130 , p. 135-142 8 p.

The risk of cardiovascular disease in irradiated breast cancer patients:The role of cardiac calcifications and adjuvant treatment

Gal R., van Velzen S. G., Emaus M. J., van den Bongard D. H., Gregorowitsch M. L., Blezer E. L., Sofie G., Lessmann N., Sattler M. G., Hooning M. J., Teske A. J., Penninkhof J. J., Meijer H., Pignol J. P., Verloop J., Išgum I., Verkooijen H. M., okt 2020, In: European Journal of Cancer. 138 , p. S6

The impact of the COVID-19 pandemic on quality of life, physical and psychosocial wellbeing in breast cancer patients – a prospective, multicenter cohort study

Bargon C., Batenburg M., van Stam L., van der Molen D. Mink, van Dam I., van der Leij F., Baas I., Ernst M., Maarse W., Vermulst N., Schoenmaeckers E., van Dalen T., Bijlsma R., Young-Afat D., Doeksen A., Verkooijen H., okt 2020, In: European Journal of Cancer. 138 , p. S17

The MOMENTUM Study:An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy

de Mol van Otterloo Sophie R., Christodouleas John P., Blezer Erwin L.A., Akhiat Hafid, Brown Kevin, Choudhury Ananya, Eggert Dave, Erickson Beth A., Faivre-Finn Corinne, Fuller Clifton D., Goldwein Joel, Hafeez Shaista, Hall Emma, Harrington Kevin J., van der Heide Uulke A., Huddart Robert A., Intven Martijn P.W., Kirby Anna M., Lalondrelle Susan, McCann Claire, Minsky Bruce D., Mook Stella, Nowee Marlies E., Oelfke Uwe, Orrling Kristina, Sahgal Arjun, Sarmiento Jeffrey G., Schultz Christopher J., Tersteeg Robbert J.H.A., Tijssen Rob H.N., Tree Alison C., van Triest Baukelien, Hall William A., Verkooijen Helena M., 7 sep 2020, In: Frontiers in oncology. 10 , p. 1328 9 p.

Problems and Promises of Introducing the Magnetic Resonance Imaging Linear Accelerator Into Routine Care:The Case of Prostate Cancer

Hehakaya Charisma, Van der Voort van Zyp Jochem R, Lagendijk Jan J W, Grobbee Diederick E, Verkooijen Helena M, Moors Ellen H M 2 sep 2020, In: Frontiers in oncology. 10 11 p.

The effect of neoadjuvant short-course radiotherapy and delayed surgery versus chemoradiation on postoperative outcomes in locally advanced rectal cancer patients - A propensity score matched nationwide audit-based study

Hoendervangers S, Sparreboom C L, Intven M P W, Lange J F, Verkooijen H M, Doornebosch P G, van Grevenstein W M U sep 2020, In: European Journal of Surgical Oncology. 46 , p. 1605-1612 8 p.

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE):study protocol for a trial within a cohort study

Schraa S J, van Rooijen K L, van der Kruijssen D E W, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé V M H, van Grevenstein W M U, Elias S, Verkooijen H M, Laclé M M, Bosch L J W, van den Broek D, Meijer G A, Velculescu V E, Fijneman R J A, Vink G R, Koopman M, 20 aug 2020, In: BMC Cancer. 20 10 p.

All Research Output (289)